ArticleInfection and drug resistance2026
Diosgenin Promotes Bacterial Clearance in Bladder Epithelial Cells by Regulating Rab27b Expression: A Study Based on Virtual Screening and Experimental Validation.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The annual rise in antimicrobial resistance (AMR) rates highlights the critical significance of exploring non-antibiotic therapies for infectious diseases. Urinary tract infection (UTI) is one of the most common bacterial infectious diseases, and uropathogenic Escherichia coli (UPEC), its primary pathogenic bacterium, invades bladder epithelial cells (BECs) to survive and proliferate intracellularly, thereby evading the host's immune clearance. Rab27b mediates the expulsion of intracellular bacteria, and upregulating Rab27b expression can effectively reduce the number of intracellular bacteria. Methods: In this study, virtual screening and molecular dynamics simulation were used to screen for compounds capable of stably binding to Rab27b. Surface plasmon resonance (SPR) was subsequently performed to validate the direct binding affinity of diosgenin (DSG) to Rab27b. The CCK-8 assay was adopted to determine the experimental concentrations of the compounds for cellular experiments. Western blot (WB), immunofluorescence (IF), colony counting, siRNA transfection and other assays were used to clarify the effects of the screened compounds on Rab27b expression and the number of intracellular bacteria in BECs. Additionally, IF, hematoxylin-eosin (HE) staining, scanning electron microscopy (SEM), and colony counting were employed to investigate the impacts of DSG on Rab27b expression, epithelial integrity, the number of intracellular bacterial CFU, and inflammatory responses in the bladder of mice with UPEC-induced UTI models. Results: Virtual screening and experimental validation demonstrated that DSG and ST5330591 (ST) could stably bind to Rab27b. DSG upregulated Rab27b protein expression without affecting its mRNA level, suggesting a post-transcriptional mechanism, which contributes to accelerated intracellular bacterial clearance. After Rab27b downregulation via siRNA transfection, DSG lost its ability to clear intracellular bacteria. Furthermore, DSG reduced the number of intracellular Colony-Forming Unit (CFU) in BECs of mice with urinary tract infection, alleviated bladder inflammatory responses, and mitigated the efflux and damage of the bladder epithelial layer. Conclusion: This study demonstrated that DSG directly binds to Rab27b and upregulates its protein expression via a post-transcriptional mechanism (without altering mRNA levels), thereby promoting the clearance of intracellular UPEC in BECs and exerting therapeutic effects on UTI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.